The European Rare Disease Models & Mechanisms Network (RDMM-Europe) has been established by Solve-RD – an EU-funded research project. The overall aim is to boost research in rare diseases, discover new disease-causing genes and obtain evidence for pathogenicity through functional validation.

For more information, visit the following website.

The European Rare Disease Models & Mechanisms Network (RDMM-Europe) has been established by Solve-RD – an EU-funded research project. The overall aim is to boost research in rare diseases, discover new disease-causing genes and obtain evidence for pathogenicity through functional validation.

For more information, visit the following website.

A call on research and innovation's actions will be launched on July 18, 2019. IMI projects aim at accelerating the medicines development process, generating new scientific insights, and developing resources for open use by the research community. The topics of this call are related to integrated research platforms, digital clinical trials, immune-mediated diseases, medicines safety, brain disorders, blockchain, antimicrobial resistance.

FInd more information on the following link.

The International Summer School on Rare Disease Registries and FAIRification of Data is a part of a series of training activities proposed by the European Joint Programme on Rare Diseases (EJP RD) which will take place at the Istituto Superiore di Sanità, Rome, Italy. The first module “Rare Disease Registries” starts on September 23 till September 25, 2019. The second module “FAIRification of data”, starts on September 26 till September 27, 2019.

Onlne registration deadline is June 20th, 2019.

Find more information on the following link.

The European Joint Programme on Rare Diseases (EJP RD), which is the successor of E-Rare launches the Joint Transnational Call 2019. The call will  open officially in December. This year projects should focus on accelerated diagnosis and/or exploration of disease progression and mechanisms of rare diseases. More info under www.ejprarediseases.org

Programs to access to clinical compounds

Programs to access to clinical compounds

In order to access to clinical compounds, pharmaceutical companies like AstraZeneca or Pfizer, are developping programs to propose number of their molecules that could be used in repurposing studies.

AstraZeneca Open innovation Program

In addition to marketed and Ph 3 compounds listed on the company’s website, AstraZeneca invites meritorious scientific proposals to study selected additional Ph 2a ready compounds (mechanisms) listed on their Open Innovation platform in a Clinical Table of Compounds.  To discuss the suitability of one of these compounds and, if mutually deemed warranted, obtain a ‘Letter of Support’ for AstraZeneca to supply the formulated compound as well as matched placebo contact Dr. Craig Wegner at craig.wegner[at]astrazeneca.com.  For clarity, review for and funding of the final full proposal would still be through this E-Rare-3 Call for Proposals, but AstraZeneca would, assuming they agree, provide compound, technical expertise related to the compound as well as clinical study, and supportive regulatory documents.

More information

Pfizer Compound transfer program
Pfizer has an extensive pure substance library that encompasses all of their publicly known compounds. You can submit a request for a Pfizer compound by going on INSPIIRE portal. Each request regarding use of their compounds will be reviewed for content, value, and consistency with Pfizer's direction for the requested compound. For approved requests Pfizer executes Compound Transfer Agreements (CTAs) that provide the compound free of charge to a third party to conduct the agreed upon study. Processing time from initial submission to the approved compound(s) shipment to your facility may take up to 12 weeks.

More information

E-Rare 2012 - Created by Toussaint Biger